Live Breaking News & Updates on Eutralisation Data

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs). ....

South Korea , Inch On Gwangyoksi , Donna Curran , National Institutes Of Health , European Medicines Agency , Celltrion Group , Committee For Medicinal Products Human Use , Marketing Division At Celltrion Healthcare , National Institutes , Houng Kim , Marketing Division , Medicinal Products , Human Use , Celltrion Healthcare , Media Contact , R Houng Kim , Cocktail Therapy , Eutralisation Data , Omicron Variant , Lobal Phase I , Ct P63 , X Ray Crystallography , Structural Analysis , Trong Neutralising , Seudo Virus Testing , Ebulised Cocktail Therapy ,